Moberg Pharma
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gustavslundsvägen 42, Bromma, Stockholm,...Phone Number
+46 852230700Website
www.mobergpharma.comRevenue
$48 MillionStock Symbol
MOB.STIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Moberg Pharma
Moberg Pharma is a Swedish specialty pharmaceutical company focused on dermatology, developing innovative treatments for nail fungus. Their product, MOB-015, is a topical solution approved in 13 EU countries, aimed at improving treatment outcomes for patients suffering from onychomycosis. The company emphasizes strong clinical efficacy and ease of use, targeting millions of patients worldwide. With a business model that reduces development risk, Moberg Pharma aims to bring effective solutions to market quickly.Explore more
Popular SearchesMoberg Pharma AbMoberg PharmaMoberg Pharma North America LLCMoberg DermaMoberg Pharma AB( PublSIC Code 28,283NAICS Code 32,325Ticker STO: MOB.STShow moreMoberg Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moberg Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Moberg Pharma is spiking on competitors!
Product Launch: Get notified when Moberg Pharma launches new products
Check if Moberg Pharma has recently received funding, and reach out quickly before it becomes old news!
Moberg Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Moberg Pharma
Funding: Get notified immidiatlly once Moberg Pharma has new funding data
Click to see if Moberg Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Moberg Pharma recently announced quarterly report
Recommended Actions
Find VP level buyers at Moberg Pharma
Find 3 more new buyers
Company Profile Activity
Activity Insights
Moberg Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Moberg Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Moberg Pharma.
Moberg Pharma Tech Stack
A closer look at the technologies used by Moberg Pharma
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
Project
Product Development, Research & Development
Left Company
Executive Move
Torbjörn Wärnheim, Deputy Chief Executive Officer & Senior VP, Research & Development, has left the organization and now serves as the Head of Research & Development at Olink.
Left Company
Executive Move
Moberg Pharma News & Media
The board of directors exercises authorizations to issue and repurchase C-shares ... - Cision News
Moberg Pharma AB (publ) today announces that the board of directors exercises authorizations toTerclara (MOB-015) is now being launched in Norway
STOCKHOLM, Feb. 3, 2025 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) and Allderma today announce that the launch of Terclara® (MOB-015) is ongoing in Norway. The launch marks an important step in both companies' commercial strategy and builds on the successful launch in Sweden, where...Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM, Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The company's focus going forward will be on the...Moberg Pharma’s Nomination Committee appointed
STOCKHOLM, November 8[th], 2024 – In accordance with the resolution of the Annual General Meeting on May 14[th], 2024, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s two largest
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Moberg Pharma
Sign Up For FreeTo access detailed company insights
Moberg Pharma is a Swedish specialty pharmaceutical company focused on dermatology, developing innovative treatments for nail fungus. Their product, MOB-015, is a topical solution approved in 13 EU countries, aimed at improving treatment outcomes for patients suffering from onychomycosis. The company emphasizes strong clinical efficacy and ease of... Read More
